Active lupus nephritis
Conditions
Interventions
A:MMF 0.75~1.0g/d in induction stage, MMF0.5~0.75g/d in maintenance stage
B:FK506 0.1mg/kg/d in induction stage, FK506 0.05mg/kg/d in maintenance stage
C:Intravenous CYC was given in monthly pulses of 0.5-0.75g/m2 in induction stage, Aza 1-2mg/kg/d in maintenance stage
Sponsors
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai, China
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients who aged 18 to 65 years and had a diagnosis of systemic lupus erythematosus, as defined by the 1997 revised American Rheumatism Association criteria; 2. Renal biopsy showing active lupus nephritis (classes III, IV-S or IV-G, V, III+V, or IV+V according to the 2003 International Society of Nephrology/Renal Pathology Society classification); 3. urinary protein excretion of 1.0 g/24 h or above; 4. With informed consent signed.
Exclusion criteria
Exclusion criteria: 1. Treatment with MMF, tacrolimus, cyclosporine or IVC within the previous year; 2. Serum creatinine concentration >4.52 mg/dl (400 umol/L); 3. Life-threatening complications such as cerebral lupus, pancreatitis, gastrointestinal hemorrhage within 6 momths or active peptic ulcer within 3 months, severe infection, severe cardiovascular disease, bone marrow insufficiency with cytopenias not attributable to SLE; 4. Poor drug compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate; | — |
Countries
China
Contacts
Public ContactNan Chen
Outcome results
None listed